CLDX logo

Celldex Therapeutics Inc. (CLDX)

$28.59

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CLDX

Market cap

$2.25B

EPS

-4.31

P/E ratio

--

Price to sales

14856

Dividend yield

--

Beta

1.040183

Price on CLDX

Previous close

$28.83

Today's open

$28.59

Day's range

$28.33 - $29.08

52 week range

$22.33 - $45.14

Profile about CLDX

CEO

ANTHONY S. MARUCCI

Employees

198

Headquarters

Hampton, NJ

Exchange

NASDAQ Capital Market

Shares outstanding

78545051

Issue type

Common Stock

CLDX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CLDX

Celldex Therapeutics Targets 2027 Filing for Barzolvolimab After Phase 3 Results

Celldex Therapeutics NASDAQ: CLDX plans to submit a biologics license application for barzolvolimab in 2027, using full 52-week data from its Phase 3 studies in chronic spontaneous urticaria, executives said at Guggenheim's 3rd Annual Healthcare Innovation Conference.

news source

MarketBeat • Nov 10, 2026

news preview

Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming investor conferences: The Guggenheim 3rd Annual Healthcare Innovation Conference on November 9, 2026 at 9:00am ET.

news source

GlobeNewsWire • Nov 4, 2026

news preview

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

news source

PRNewsWire • Oct 12, 2026

news preview

Celldex's skin disease drug meets goals in two late-stage trials

Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary ​goals of two late-stage trials.

news source

Reuters • Sep 22, 2026

news preview

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Celldex Therapeutics NASDAQ: CLDX reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria, or CSU, who remained symptomatic despite H1 antihistamine treatment. The company said both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.

news source

MarketBeat • Sep 22, 2026

news preview

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.

news source

Benzinga • Sep 22, 2026

news preview

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

news source

Seeking Alpha • Sep 22, 2026

news preview

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Best-in-disease results showed rapid, profound, sustained efficacy, supporting barzolvolimab's potential to be a transformational therapy in CSU EMBARQ-CSU1 and -CSU2 met primary and all key secondary endpoints at 12 weeks across both studies and both dose groups Clinically meaningful and statistically significant benefit demonstrated in omalizumab refractory CSU and patients with severe disease or severe angioedema Efficacy sustained or deepened from weeks 12 to 24 Well tolerated with a favorable safety profile through 24 weeks; consistent with prior studies Treatment will continue in both trials to 52 weeks; BLA submission anticipated in 2027 Company to host webcast today at 8:00 am ET HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company's Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.

news source

GlobeNewsWire • Sep 22, 2026

news preview

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

news source

Zacks Investment Research • Sep 22, 2026

news preview

Celldex to Present at Upcoming Investor Conference

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

news source

GlobeNewsWire • Sep 8, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Celldex Therapeutics Inc.

Open an M1 investment account to buy and sell Celldex Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CLDX on M1